MAP2K4 (Ab-80) Antibody

What is MAP2K4 (Ab-80) Antibody and what cellular pathways does it help investigate?

MAP2K4 (Ab-80) Antibody is a rabbit polyclonal antibody that specifically detects endogenous levels of MAP2K4 (also known as MKK4, MEK4, or SEK1) when phosphorylated at Serine 80 . This antibody is a critical tool for investigating the MAP kinase signal transduction pathway, particularly the stress-activated protein kinase/c-Jun N-terminal kinase (SAP/JNK) signaling pathway .

MAP2K4 functions as a dual specificity protein kinase that, together with MAP2K7/MKK7, directly activates the stress-activated protein kinases MAPK8/JNK1, MAPK9/JNK2, and MAPK10/JNK3 through phosphorylation . Unlike MAP2K7/MKK7 which exclusively activates JNKs, MAP2K4 additionally activates p38 MAPKs including MAPK11, MAPK12, MAPK13, and MAPK14 . This antibody is therefore essential for researchers studying stress responses, apoptosis, inflammation, and cancer development.

What are the validated applications for MAP2K4 (Ab-80) Antibody?

MAP2K4 (Ab-80) Antibody has been validated for multiple experimental applications:

The antibody has been cited in multiple publications, demonstrating its reliability across these applications . Researchers should optimize the dilution for their specific experimental conditions and sample types.

What species reactivity has been confirmed for this antibody?

The MAP2K4 (Ab-80) Antibody has been validated to react with:

• Human samples

• Mouse samples

• Rat samples

Positive Western blot detection has been specifically confirmed in K-562 cells, HeLa cells, RAW264.7 cells, mouse brain tissue, and human breast cancer tissue . This broad species reactivity makes it versatile for comparative studies across different model systems.

How should I optimize western blot protocols when using MAP2K4 (Ab-80) Antibody?

When optimizing western blot protocols with MAP2K4 (Ab-80) Antibody, consider the following methodological approach:

• Sample preparation: MAP2K4 protein is observed at 44-50 kDa molecular weight range . Use appropriate lysis buffers that preserve phosphorylated proteins, ideally containing phosphatase inhibitors to prevent dephosphorylation of Ser80.

• Loading control: Given MAP2K4's role in signaling pathways, normalize loading using housekeeping proteins such as GAPDH or β-actin.

• Dilution optimization: Start with 1:1000 dilution and adjust based on signal strength . For phospho-specific detection, a dilution range of 1:500-1:2000 is recommended for optimal results.

• Incubation conditions: Primary antibody incubation should be performed overnight at 4°C to maximize specific binding while minimizing background.

• Detection system: Use an appropriate anti-rabbit secondary antibody conjugated to HRP or fluorescent tags based on your detection system.

• Controls: Include both positive controls (such as HeLa or K-562 cells, which have been confirmed to express MAP2K4) and negative controls (such as MAP2K4 knockout or silenced cells) to validate specificity.

What are the critical considerations for immunohistochemistry applications using this antibody?

For successful immunohistochemistry with MAP2K4 (Ab-80) Antibody:

• Antigen retrieval: The optimal method involves using TE buffer at pH 9.0, though citrate buffer at pH 6.0 can serve as an alternative . Effective antigen retrieval is particularly critical for phospho-specific antibodies.

• Tissue preparation: The antibody has been validated on formalin-fixed, paraffin-embedded sections of human liver cancer tissue, human breast cancer tissue, and human skeletal muscle tissue .

• Dilution range: Use a dilution of 1:50-1:500, optimizing based on your specific tissue type and detection system .

• Blocking: Implement thorough blocking to minimize background, especially important when studying tissues with high endogenous peroxidase activity.

• Counterstaining: Use appropriate nuclear counterstains (such as hematoxylin) to provide cellular context for the MAP2K4 phospho-Ser80 signal.

• Visualization: The antibody has been validated with both chromogenic and fluorescent detection systems; select based on your research needs.

How can MAP2K4 (Ab-80) Antibody be utilized to investigate oncogenic pathways in breast cancer?

Recent research has revealed MAP2K4's complex role in breast cancer, with the antibody against phospho-Ser80 serving as a critical tool in this investigation:

• Proliferation studies: MAP2K4 overexpression has been shown to markedly promote cell growth and G1 to S cell-cycle transition in breast cancer cell lines MCF-7 and MDA-MB-231 . The phospho-Ser80 antibody can monitor activation status during proliferation studies.

• Migration and invasion assays: Research has demonstrated that MAP2K4 promotes breast cancer cell migration and invasion both in vitro and in vivo . MAP2K4 (Ab-80) Antibody can be used in Transwell and Boyden assays to correlate phosphorylation status with migratory phenotypes.

• PI3K/AKT pathway activation: MAP2K4 has been demonstrated to activate the PI3K/AKT pathway in breast cancer cells . Researchers can use this antibody alongside PI3K/AKT pathway markers to investigate this cross-talk.

• Vimentin interaction: MAP2K4 has been shown to interact with Vimentin in breast cancer cells , suggesting its role in epithelial-mesenchymal transition. Co-immunoprecipitation studies using this antibody can help validate these protein-protein interactions.

• In vivo xenograft models: The antibody can be used for immunohistochemical analysis of tumor tissues from xenograft mice to correlate MAP2K4 phosphorylation with tumor growth and markers like PCNA and Ki-67 .

What is the role of MAP2K4 phosphorylation at Ser80 specifically in stress response signaling?

MAP2K4 phosphorylation at Ser80 represents a specific regulatory mechanism in stress response signaling:

• Activation mechanism: Unlike the canonical activating phosphorylations at Ser257 and Thr261 by upstream MAP3Ks , Ser80 phosphorylation represents an additional regulatory site that may modulate MAP2K4 activity in response to specific stressors.

• JNK pathway specificity: MAP2K4 shows preference for phosphorylating the Tyr residue in the Thr-Pro-Tyr motif of JNKs, while MAP2K7/MKK7 preferentially phosphorylates the Thr residue . This differential preference contributes to signaling specificity in response to various stimuli.

• Pro-inflammatory cytokine response: While MAP2K7/MKK7-mediated Thr phosphorylation appears to be prerequisite for JNK activation in response to pro-inflammatory cytokines, other stimuli activate both MAP2K4 and MAP2K7, which synergistically phosphorylate JNKs .

• Apoptotic signaling: The MKK/JNK signaling pathway is involved in mitochondrial death signaling, including cytochrome c release leading to apoptosis . The phospho-Ser80 antibody can help determine if this specific phosphorylation site plays a role in apoptotic decisions.

How can MAP2K4 (Ab-80) Antibody be used to study RAS/MAPK inhibitor resistance mechanisms?

Recent research has identified MAP2K4 as a potential therapeutic target to overcome resistance to RAS/MAPK pathway inhibitors:

• Combinatorial drug studies: Research has shown that genetic inactivation of MAP2K4 greatly enhances sensitivity to MEK and ERK inhibitors in KRAS-mutant tumors . MAP2K4 (Ab-80) Antibody can be used to monitor phosphorylation status during combinatorial drug treatments.

• Synergistic effects with RAS inhibitors: The recently developed MAP2K4 inhibitor HRX-0233 shows synergistic effects with KRAS inhibitors such as sotorasib and RMC-6236 . Western blot analysis with this antibody can determine if drug efficacy correlates with reduced Ser80 phosphorylation.

• Assessing drug specificity: In studies comparing wild-type and MAP2K4 knockout cells, this antibody can help verify that observed effects of MAP2K4 inhibitors are indeed target-specific rather than off-target effects .

• Resistance mechanism profiling: By examining phospho-MAP2K4 levels in resistant versus sensitive cell lines, researchers can determine if aberrant MAP2K4 signaling contributes to therapy resistance.

• Patient sample analysis: The antibody can be used for immunohistochemical analysis of patient-derived xenografts or tissue microarrays to correlate MAP2K4 phosphorylation status with response to RAS/MAPK pathway inhibitors.

What are the potential causes and solutions for non-specific binding when using MAP2K4 (Ab-80) Antibody?

When troubleshooting non-specific binding issues:

• Antibody dilution: Suboptimal dilution can lead to high background. Titrate the antibody within the recommended range (1:500-1:2000 for WB; 1:50-1:500 for IHC) .

• Blocking optimization: Insufficient blocking often causes non-specific binding. Use 5% non-fat dry milk or 3-5% BSA in TBS-T for western blots, and appropriate blocking sera for IHC applications.

• Cross-reactivity: The antibody may cross-react with related kinases. Verify specificity using MAP2K4 knockout or silenced samples as negative controls .

• Washing stringency: Inadequate washing can leave non-specifically bound antibody. Increase the number or duration of wash steps with TBS-T or PBS-T.

• Sample preparation: Improper sample preparation can expose epitopes that promote non-specific binding. Ensure proper fixation for IHC and appropriate lysis/denaturation for western blots.

• Secondary antibody issues: Excessive secondary antibody can increase background. Titrate and ensure it is compatible with the host species (rabbit) of the primary antibody.

How can I validate the specificity of MAP2K4 (Ab-80) Antibody in my experimental system?

To validate antibody specificity:

• Phosphatase treatment: Treat half of your sample with lambda phosphatase to remove phosphorylation at Ser80. The antibody signal should be abolished in the treated sample but retained in the untreated control.

• siRNA knockdown: Perform MAP2K4 silencing using validated siRNA sequences . Compare phospho-Ser80 signal between control and knockdown samples.

• CRISPR/Cas9 knockout: Generate MAP2K4 knockout cells as a definitive negative control .

• Peptide competition assay: Pre-incubate the antibody with a synthetic phosphopeptide containing the Ser80 phosphorylation site. This should block specific antibody binding and eliminate the genuine signal.

• Stimulation conditions: Treat cells with known activators of the MAP2K4 pathway (such as stress stimuli, cytokines) to increase phosphorylation at Ser80, thereby enhancing the specific signal.

• Phosphosite mutants: Express MAP2K4 with a S80A mutation that cannot be phosphorylated at this site. This should not be detected by the phospho-specific antibody.

How should researchers interpret discrepancies between total MAP2K4 and phospho-Ser80 MAP2K4 levels?

When total MAP2K4 and phospho-Ser80 MAP2K4 levels show discrepancies:

• Post-translational regulation: Discrepancies may indicate changes in phosphorylation status rather than protein expression. This suggests activation/deactivation events are occurring within existing protein pools.

• Signaling dynamics: Rapid and transient phosphorylation events may cause temporal mismatches between total and phosphorylated protein. Consider time-course experiments to capture these dynamics.

• Subcellular localization: Phosphorylation may trigger relocalization of MAP2K4. Compare cellular distribution using immunofluorescence with both antibodies.

• Pathway crosstalk: MAP2K4 is at the intersection of multiple signaling pathways, including JNK and p38 MAPK pathways . Differential phosphorylation might indicate pathway crosstalk or selectivity.

• Technical factors: Different detection sensitivities between antibodies may cause apparent discrepancies. Normalize signals appropriately and consider using multiple detection methods.

• Degradation mechanisms: Phosphorylation can sometimes trigger protein degradation. Consider whether phosphorylated MAP2K4 is being selectively degraded following activation.

How can MAP2K4 (Ab-80) Antibody be integrated with other markers to comprehensively profile cancer signaling networks?

For comprehensive cancer signaling network profiling:

• Multiplex immunostaining: Combine MAP2K4 (Ab-80) Antibody with antibodies against downstream targets (JNK, p38) and parallel pathway components (PI3K/AKT) to visualize pathway activation patterns within the same tissue sections.

• Reverse phase protein arrays (RPPA): Incorporate MAP2K4 (Ab-80) Antibody into RPPA panels to quantitatively assess phospho-Ser80 levels alongside dozens to hundreds of other signaling proteins.

• Phospho-flow cytometry: Adapt the antibody for phospho-flow protocols to simultaneously measure MAP2K4 phosphorylation and other signaling events at the single-cell level.

• Proximity ligation assays: Combine MAP2K4 (Ab-80) Antibody with antibodies against interacting proteins such as Vimentin to directly visualize and quantify protein-protein interactions in situ.

• Correlation with proliferation markers: As MAP2K4 has been shown to promote cell growth, combine with proliferation markers such as PCNA and Ki-67 in tissue analysis .

• Integration with drug response data: Correlate phospho-MAP2K4 levels with sensitivity to RAS pathway inhibitors like sotorasib, RMC-6236, trametinib, and SCH772984 to identify biomarkers of response.

• Multi-omics integration: Correlate protein-level data from the antibody with transcriptomic and genomic data to build comprehensive models of signaling networks.

What are the best practices for using MAP2K4 (Ab-80) Antibody in patient-derived samples for translational research?

For translational research with patient-derived samples:

• Tissue processing standardization: Standardize fixation protocols (time, fixative) to ensure consistent phospho-epitope preservation across samples.

• Rapid sample processing: Process samples quickly after collection to preserve phosphorylation status, as phospho-epitopes can be labile.

• Control samples: Include both positive (known MAP2K4-phosphorylated) and negative (phosphatase-treated) control tissues in each batch of patient samples.

• Sequential staining: In limited samples, consider sequential immunostaining approaches to maximize data collection from the same tissue section.

• Automated platforms: Validate the antibody on automated staining platforms to enhance reproducibility across large patient cohorts.

• Phospho-preservation: Explore phospho-preservation protocols such as adding phosphatase inhibitors during tissue collection and processing.

• Digital pathology: Implement quantitative digital pathology approaches to objectively measure phospho-MAP2K4 levels across heterogeneous tumor regions.

• Clinical correlation: Correlate phospho-MAP2K4 levels with clinical outcomes and response to therapies to establish its potential as a prognostic or predictive biomarker.

How can ChIP-seq be combined with MAP2K4 (Ab-80) Antibody to understand transcriptional regulation by this signaling pathway?

Although MAP2K4 is primarily a cytoplasmic signaling kinase, its pathway culminates in transcription factor activation. Researchers could:

• Sequential ChIP approach: First, perform ChIP with antibodies against downstream transcription factors (c-Jun, ATF2) activated by the MAP2K4 pathway, followed by assessment of target gene occupancy.

• Pathway stimulation: Treat cells with pathway activators, then compare transcription factor binding patterns to identify MAP2K4-dependent binding events.

• Inhibitor studies: Compare ChIP-seq profiles with and without MAP2K4 inhibitors (like HRX-0233) or after MAP2K4 silencing to identify dependent transcriptional events.

• Nuclear MAP2K4 investigation: Though primarily cytoplasmic, MAP2K4 can localize to the nucleus . Use the phospho-antibody in ChIP to investigate whether phosphorylated MAP2K4 directly associates with chromatin in some contexts.

• Phospho-transcription factor ChIP: Use antibodies against phosphorylated forms of downstream transcription factors, correlating their binding patterns with MAP2K4 phosphorylation status.

• Integration with phosphoproteomics: Combine ChIP-seq data with phosphoproteomic profiling using methods that can capture MAP2K4 (Ab-80) epitopes to correlate pathway activation with transcriptional changes.

• Time-course analysis: Perform time-course experiments following MAP2K4 pathway activation to capture the temporal dynamics of transcription factor binding and gene expression changes.